CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic,
Inc. (Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced the appointment of David
Hava, Ph.D. as Chief Scientific Officer. Dr. Hava will
provide strategic leadership to the research organization
and build Synlogic's portfolio of research partners. Dr.
Hava is an experienced drug developer and CSO with a demonstrated
track record of taking assets into the clinic and generating
partnerships which build clinical and scientific value. He has
previously served as Chief Scientific Officer at Metera
Pharmaceuticals and Pulmatrix.
"We are thrilled to welcome Dave to the
Synlogic executive team. His deep experience in
developing drugs and leveraging strategic partnerships will
further strengthen our synthetic biology research engine and
provide critical scientific vision to support successful
advancement of our Synthetic Biotic platform," said
Aoife Brennan, M.B. Ch.B.,
Synlogic's president and chief executive officer.
"I am delighted to join Synlogic. The research team
has built the premier scientific and
technology platform for engineered bacterial Synthetic
Biotic medicines.," said David Hava, Ph.D., Synlogic's
Chief Scientific Officer. "I have great enthusiasm for the
potential of these unique medicines to provide clinical benefit.
Now is an opportune time for me to join the team given the
rapid clinical and preclinical progression of
programs against multiple metabolic and immunology
targets."
Dr. Hava brings more than a decade of senior experience in
research and development to Synlogic, including deep academic
expertise in pillars of synthetic biology. Prior to joining
Synlogic, David served as CSO at Metera Pharmaceuticals. David has
also served as CSO at Pulmatrix Inc., where he led the Research and
Development organization in the company's development of their
delivery platform. David has co-authored dozens of papers and
abstracts focusing on immunology, pulmonary infectious disease and
chronic lung diseases, advanced four assets into the clinic, and
executed multiple value creating research and clinical
partnerships.
Dr. Hava earned his Ph.D. in Molecular Biology and Microbiology
at Tufts University and completed his
post-doctoral training at Harvard Medical
School studying immunology and host-pathogen
interactions.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
The company is also building a portfolio of partner-able assets in
immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials and availability of
clinical trial data. Actual results could differ materially from
those contained in any forward-looking statement as a result of
various factors, including: the uncertainties inherent in the
clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synlogic-appoints-david-hava-phd-as-chief-scientific-officer-301128439.html
SOURCE Synlogic, Inc.